Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests

Sohag University

Status: Not yet enrolling

Conditions: Multiple Myeloma

Treatments: Procedure: Bone marow biopsy and aspiration; Diagnostic Test: biochemical and heamatological tests

Study type: Interventional

Funder types: Other

Identifiers

NCT05995808

Soh-Med-23-07-02MD

Details and patient eligibility

About

Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and takes the second place after non-Hodgkin lymphoma .

There are some serological and clinical criteria that help to detect the stage of MM and predict the patients' prognosis. These criteria include the level of M protein, calcium, haemoglobin, albumin, creatinine, β2-microglobulin and glomerular filtration rate (GFR).

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients older than 18 year with newly diagnosed MM.
2. Approval to sign an informed written consent.

Exclusion criteria

• 1. Patient younger than 18 years. 2.Refusal to sign an informed written consent.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

diagnostic group

Experimental group

Treatment:

Diagnostic Test: biochemical and heamatological tests

Procedure: Bone marow biopsy and aspiration